New England Journal of Medicine· 2020Q1· Clinical trial

Remdesivir for the Treatment of Covid-19 — Final Report

John H. Beigel, Kay M Tomashek, Lori E. Dodd, Aneesh K. Mehta et al.

7,738citations
Q1SCImago
2020year

Short summary

Intravenous remdesivir significantly shortened the time to recovery for hospitalized COVID-19 patients with lower respiratory tract infection, reducing it from 15 days to 10 days compared to placebo.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Infectious Diseases

Infectious DiseasesMedicine